Background: Although myeloperoxidase (MPO) and adenosine-deaminase (ADA) levels are markers of activated leukocytes, both enzymes have not been currently addressed in inflammation models.

Aims: This study evaluates whether the concentrations of these enzymes are significantly correlated with the content of leukocytes in a pleurisy model.

Methods: The pleurisy was induced by carrageenan (1%) in mice, and the parameters analyzed 4 and 48 h after.

Results: After the induction of inflammation (4 h), MPO and ADA levels peaked in parallel to neutrophils \( (p < 0.01) \). Regarding the second phase of pleurisy (48 h), the highest concentrations of ADA were detected in parallel to the highest levels of mononuclears \( (p < 0.01) \). A significant positive correlation was found among neutrophils and MPO, and mononuclears and ADA \( (p < 0.01) \).

Conclusions: These findings support the evidence that both enzymes are markers of the inflammatory process, and provide new tools for a better understanding of the immunoregulatory pathways that occur in inflammation.

Key words: Adenosine-deaminase, Myeloperoxidase, Mouse pleurisy, Inflammation

Introduction

Many studies have demonstrated that the release of myeloperoxidase (MPO) or adenosine deaminase (ADA) from leukocytes at the site of injury reflects the activation of both neutrophils and lymphocytes.\(^1,2\) Myeloperoxidase is a leukocyte component able to generate potent microbial products and it is recognized that it facilitates cell adhesion, mainly via CD11b/CD18, a function that may be of considerable importance for leukocyte migration.\(^3,4\) In addition, ADA activity originates from the action of isoenzymes ADA-1 and ADA-2. Increased ADA activity has been found in the pleural fluid and serum of tuberculous patients as well as in the serum of patients suffering from leprosy, cutaneous leishmaniosis, brucellosis, salmonellosis and human deficiency virus infection. It has also been found in subjects with renal allograft transplants undergoing acute graft rejection.\(^1,5–10\) On the contrary, based on these findings, these two markers constitute valuable tools for use in the evaluation of the degree of inflammation.\(^1,4\)

Since very little data is available regarding the changes in the two enzymes during acute and/or chronic inflammation, the aim of the present study was to examine whether the concentrations of both enzymes are significantly correlated with the differential contents of leukocyte cells, namely neutrophils and lymphocytes, in a pleurisy model induced by carrageenan (1%) in mice. A major characteristic of this model is the biphasic profile of cell migration characterized by an early (4 h) and late (48 h) cell migration of neutrophils and mononuclear cells, respectively.\(^11\) These two phases of the inflammatory response to carrageenan in the mouse pleural cavity are named ‘first’ (or ‘early’) and ‘second’ (or ‘late’) phases.

Methods

Animals

Non-fasted adult Swiss mice of both sexes (18–25 g), aged 2 months, were used throughout the experiments. The animals were kept in an environmentally controlled room, temperature 21 ± 2°C, under a light/dark cycle of 12 h, and were allowed free access to food and water. Animals were managed using the principles and guidelines for the care of laboratory animals according to Zimmermann.\(^12\)

Experimental design

Induction and analysis of pleurisy

As previously reported,\(^11,13\) the mouse pleurisy was induced by a single intrapleural injection of 0.1 ml of
sterile saline plus carrageenan (1%). Since the pleurisy caused by carrageenan exhibits a biphasic response (4 and 48h), both interval points were chosen to determine the levels of both MPO and ADA.

After killing the animals with an overdose of ether, the thorax was opened and the pleural cavity was washed with 1.0 ml of sterile phosphate-buffered saline (PBS) containing heparin (20 IU/ml). Several samples of the pleural lavage were collected for further determination of both MPO and ADA activities as well as total and differential leukocyte contents. Total leukocyte counts were performed on an automatic counting machine (Beckman Coulter, Inc., Brea, CA, USA), whereas cytopsin preparations of pleural washing were stained with May-Grunwald-Giemsa for the differential count of leukocytes, which was performed under an immersion objective.

Enzymatic assays
In-house assays of both MPO and ADA were employed according to the methods developed by Rao et al. and Giusti and Galanti. Using conventional reagents, each enzymatic concentration was estimated by means of colorimetric measurements (absorbances at 450 and 630 nm, respectively) in a Hitachi spectrophotometer (U-2001, San Jose, CA, USA). One unit of MPO is defined as the activity of the enzyme that oxides 1 mol of H$_2$O$_2$/min, whereas one unit of ADA is equivalent to the amount of enzyme required to release 1 mmol of ammonia/min. Results were expressed as mU/ml (MPO) and U/l (ADA).

Myeloperoxidase assay
Standard samples with different concentrations of myeloperoxidase (from human neutrophils, M6908, St. Louis, MO, USA) were prepared to obtain a standard curve in the range of 0.07–140 mU/ml. Pleural aliquots (40 µl) and standards were transferred to cuvettes and the reaction was initiated with the addition of 360 µl of assay buffer (0.167 mg/ml of o-dianisidine 2HCl and 0.0005% H$_2$O$_2$). The reaction was stopped with sodium azide 1%. Afterwards, the samples were centrifuged at 50 × g for 5 min, the supernatants were separated, and the rates of changes in absorbancy were determined. MPO activity was estimated by interpolation from the standard curve already described. Samples in which the levels of MPO were above the higher limit of detection (140 mU/ml) were diluted (two- to fivefold) and the concentrations were corrected for the twofold to fivefold dilution, whereas results below the lower limit of detection were expressed as 0.7 mU/ml.

Adenosine-deaminase assay
Initially, standard samples (final volume of 500 µl) with different volume concentrations of NaH$_2$PO$_4$·H$_2$O (35 mM), Na$_2$HPO$_4$·12H$_2$O (15 mM) and of NH$_3$SO$_4$ (15 mM) were prepared to obtain a standard curve in the range of 10–50 U/l. Pleural fluid samples (20 µl) were transferred to cuvettes and the reaction was initiated by the addition of adenosine phosphate-buffered solution (pH 6.5, 500 µl; composition, NaH$_2$PO$_4$·H$_2$O (35 mM), Na$_2$HPO$_4$·12H$_2$O (15 mM) and adenosine (0.5 mM)). After incubation for 1 h at 37°C, the reaction was halted with the addition of a solution (1000 µl) of phenol (1 mM) and nitroprussiate (0.17 mM), plus alkaline buffer (1000 µl: NaOCl, 11 mM). This solution (final volume of 2000 µl) was also added to the cuvettes with the different standard samples. Afterwards, the rate of change in absorbancy was determined. ADA activity was estimated by interpolation from the standard curve already described. The reagents were stable at 2–8°C for 1 month.

Drugs
Carrageenan (degree IV), dianisidine 2HCl (3,3'-dimethoxybenzidine), sodium azide, human polymorphonuclear leukocyte myeloperoxidase (Sigma, St, Louis, MO, USA), NaH$_2$PO$_4$·H$_2$O, Na$_2$HPO$_4$·12H$_2$O, NH$_3$SO$_4$, nitroprussiate (Montedison, S˜ao Paulo, SP, Brazil), adenosine (Sigma, St. Louis, MO, USA), alkaline buffer (Merck, São Paulo, SP, Brazil), phenol (Biotec, São Paulo, SP, Brazil). NaCl (0.9%), May-Grunwald-Giemsa dye from different commercial sources. PBS (Merck (pH 7.6): composition, NaCl (137 mmol), KCl (2.7 mmol) and phosphate buffer salts (10 mM)) was previously prepared and maintained in the refrigerator. All drugs were kept in siliconized plastic tubes at −20°C. On the day of the experiments, the drugs were diluted to the desired concentration with sterile saline solution at room temperature.

Statistical analysis
ADA and MPO values were analyzed by use of parametric (analysis of variance and Dunnett) and non-parametric (Kruskall-Wallis and Dunn) tests. When necessary, single linear regression as well as parametric and non-parametric correlation statistical tests were also employed. $p < 0.05$ was considered indicative of significance. According to the statistical methodology, values are presented as mean ± 95% confidence limits (CL) (parametric tests, ADA), mean ± SEM (parametric tests, total and differential leukocytes) or median plus range (non-parametric tests, MPO).

Results
In control animals (treated only with buffered-saline solution), MPO and ADA concentrations were 3.0 mU/ml (range, 2.0–3.4 mU/ml) and 1.9 U/l (CL, 1.0–2.8 U/l), respectively (Fig. 1A,B). Baseline levels of neutrophil and mononuclear cells ($×10^6$) were 0.3 ± 0.1 and 0.8 ± 0.1 (Fig. 1C,D).

As shown in Fig. 1A,C, myeloperoxidase levels peaked at 4h (median, 537.5 mU/ml; range,
323.6–683.7 mU/ml) \((p < 0.01)\) after pleurisy induction in parallel with neutrophils \((4.7 \pm 0.2 \times 10^6)\).

On the contrary, adenosine-deaminase levels peaked both at 4 h (mean, 5.6 U/l; CL, 5.0–6.2 U/l) \((p < 0.01)\) and 48 h (mean, 7.5 U/l; CL, 6.8–8.0 U/l) \((p < 0.01)\) after pleurisy induction (Fig. 1B). The highest concentrations of ADA were detected at 48 h in association with highest levels of mononuclears \((6.6 \pm 0.3 \times 10^6)\) \((p < 0.01)\) (Fig. 1B,D). At this time, MPO levels (median, 158.0 mU/ml; range, 146.0–171.0 mU/ml) and neutrophils \((1.2 \pm 0.2 \times 10^6)\) still remained elevated, although at lower levels than those found at 4 h (Fig. 1A,C). It is interesting to point out that high levels of ADA were also detected 4 h after pleurisy induction in association with neutrophils, but not mononuclear cell migration (Fig. 1).

A significant positive correlation was detected between ADA levels and both total leukocyte \((r = 0.73, p < 0.01)\) and mononuclear cells \((r = 0.64, p < 0.01)\) (Fig. 2A), whereas another positive correlation

---

**FIG. 1.** Myeloperoxidase (A), adenosine deaminase (B), neutrophil (C) and mononuclear (D) values determined for the pleural lavage in the early (4 h) and late (48 h) phases of pleurisy induced by carrageenan in mice. C, Control values obtained for sterile-saline-treated mice. Symbols indicate the median (MPO) or mean (ADA, neutrophils, mononuclears) values, and the dotted lines the respective ranges (MPO) or confidence limits (ADA). **\(p < 0.01\).**

**FIG. 2.** Linear regression analysis among adenosine-deaminase and mononuclears (A), and among myeloperoxidase and neutrophil (B) levels. Symbols indicate the individual values and the dotted lines the range (MPO) or 95% CL (ADA).
was found between neutrophils and MPO \((r = 0.47, P < 0.01)\) (Fig. 2B).

**Discussion**

Our data show that both MPO and ADA levels are increased in the pleurisy reaction induced by carrageenan in mice. Considering that this model of inflammation presents a biphasic profile, characterized by two different pools of leukocyte population, these results provide additional information on the general mechanisms of inflammation.

As a rule, MPO is involved in the killing of several microorganisms and foreign cells, including bacteria, fungi, viruses, red cells, and malignant and non-malignant nuclear cells.\(^3\)\(^,\)\(^4\) This enzyme is an iron-containing heme protein located in the azurophilic granules of neutrophil granulocytes and in the lysosomes of monocytes.\(^3\)\(^,\)\(^4\) Since MPO causes significant tissue damage, several methods besides that chosen in our study are available to determine its content, including flow cytometry and immunohistochemistry methods. Its interesting to comment, however, that the measurement of neutrophil surface marker for MPO is not a reliable indicator of cell degranulation in comparison with measurement of the enzyme activity.\(^2\) On the contrary, detection of MPO inside the cells using immunohistochemical techniques provides only qualitative results.\(^2\) Our data is in agreement with that of others' studies,\(^3\)\(^,\)\(^16\)\(^,\)\(^17\) since it shows that in this model of inflammation both neutrophils and MPO peaked in parallel in response to the non-specific injury caused by carrageenan in the mouse pleural cavity. Furthermore, the significant fall in MPO levels in association with a concomitant reduction in neutrophil level 48 h later suggests that the MPO half-life is very short. In addition, the possibility that MPO release in the early phase (4 h) of the inflammatory reaction may be related with the events that triggered the late mononuclear cell migration cannot be discarded. This hypothesis is based on the fact that in models of atherosclerosis MPO has been shown to indirectly induce macrophage cell activation.\(^18\) Taken together, these findings highlight the evidence that the employed MPO assay may be used as an indirect marker of neutrophil activation in the site of the inflammatory process.\(^2\)

Regarding the role of ADA in inflammation, several items of data suggest that disturbances in purinergic signaling mediate the lung inflammation and damage observed in ADA-deficient mice.\(^19\) Recently, it has been demonstrated that this enzyme binds with the CD26 molecule expressed in some lymphocyte subsets.\(^20\) In addition, the possibility that this enzyme can interact with other cell-surface proteins opens up a new perspective for the research of the immunoregulatory mechanisms of the inflammatory process. In our work, significant levels of ADA were detected in both phases of the model of pleurisy studied. Although a positive correlation was found between ADA and mononuclear cell enhancement levels, increased concentrations of this enzyme 4 h after pleurisy induction was not clearly associated with an enhancement of mononuclear cells. These findings suggest that activation of resident cells such as pleural macrophages may be occurring at this time, since an increased enhancement of this cell is only observed 48 h after.

In summary, our data provide additional evidence that both MPO and ADA are involved in this particular model of pleurisy. Although it is not possible to draw definitive conclusions about these results, these findings provide new tools for a better understanding of the immunoregulatory pathway that occurs in inflammation.

**References**


Received 15 May 2001;
Accepted 5 June 2001
Submit your manuscripts at
http://www.hindawi.com